1/12/2015 | BKBWHY | Shire arranges $850 million short-term bank facility with Citibank to fund NPS Pharma acquisition
|
8/15/2011 | PV | NPS Pharmaceuticals plans to retire its 151/2% secured class B notes
|
8/3/2011 | CVHYPF | NPS files $150 million shelf registration for preferreds, debt, stock
|
3/31/2011 | HYLM | NPS Pharmaceuticals repays $175 million 8% class A notes due 2017
|
9/16/2010 | PP | NPS amends terms of $40 million loan, cuts amount by $36.5 million
|
8/6/2009 | PP | New Issue: NPS seals $40 million committed equity financing facility with Azimuth
|
8/6/2009 | PP | Market Commentary: GTO lifts receipt placement; NPS gets equity financing; Noront to sell flow-through shares
|
5/18/2009 | CVHY | NPS Pharmaceuticals files $150 million shelf covering stock and debt
|
10/18/2007 | CV | NPS Pharmaceuticals buys back $171.2 million 3% convertibles in tender
|
10/5/2007 | SS | Quantum Partners sells shares of NPS Pharmaceuticals, keeps 1.75% stake
|
10/3/2007 | CV | NPS Pharmaceuticals extends, boosts payout in tender offer for 3% convertibles
|
9/6/2007 | CV | NPS Pharmaceuticals begins tender offer for 3% convertibles
|
8/8/2007 | PP | Market Commentary: China Natural Resources to pocket $35 million from private placement of units
|
8/7/2007 | PP | New Issue: NPS Pharmaceuticals settles $50 million sale of convertibles
|
8/7/2007 | PP | Market Commentary: NPS Pharmaceuticals pockets $50 million; Azur wraps $48 million stock deal
|
5/15/2007 | CV | Market Commentary: Amgen holds firm; Ford gains on deal; Gold Reserve up on debut; NPS, Shuffle Master see takeout hopes
|
11/9/2006 | BT | NPS reiterated at buy by Jefferies
|
9/7/2006 | BT | JMP drops NPS at market perform
|
8/17/2006 | BT | Market Commentary: Neurocrine adds 10%; NPS up on 'Soros factor'; Vivus higher; Genitope slides 4%
|
8/4/2006 | BT | JMP keeps NPS at market perform
|
8/4/2006 | BT | NPS maintained at buy by Jefferies
|
8/3/2006 | BT | NPS Pharmaceuticals reports second-quarter loss of $39.3 million
|
6/15/2006 | BT | Merrill stops coverage of NPS Pharmaceuticals
|
6/13/2006 | BT | Jefferies reiterates NPS at buy
|
6/13/2006 | BT | NPS kept at market perform by JMP
|
6/13/2006 | BT | NPS plans to select new lead pre-clinical candidate this year
|
6/12/2006 | BT | NPS to restructure operations, cut costs
|
6/12/2006 | BT | Market Commentary: NPS Pharma drops 19% to new low; Avigen up; CV Therapeutics drops 5%; Pozen pushed up 11%
|
6/12/2006 | CV | Market Commentary: Symantec reoffers, prices deal at cheap end of talk; NPS unmoved by restructuring; Comverse slides
|
5/3/2006 | CV | Market Commentary: Cephalon falls, PDL widens on results; NPS falls, MGI climbs on FDA news; XM firm despite lawsuits
|
5/3/2006 | BT | NPS downgraded to market perform by JMP
|
5/3/2006 | BT | NPS at buy by Jefferies
|
5/3/2006 | BT | NPS downgraded to neutral by Merrill
|
5/2/2006 | BT | NPS, GlaxoSmithKline announce clinical advancement of calcilytics program
|
4/27/2006 | BT | JMP reiterates NPS at market outperform
|
4/11/2006 | BT | Market Commentary: NitroMed, Antigenics strike new lows; NPS Pharma, Insmed gain; Medtronic deal boosts Biomet
|
3/14/2006 | BT | NPS keeps market outperform rating from JMP
|
3/13/2006 | BT | Jefferies rates NPS at buy
|
3/13/2006 | BT | Merrill maintains NPS at buy
|
3/13/2006 | BT | Market Commentary: NitroMed off on data; NPS gains 7%; Vasogen falls on trial failure; Medicines up 10%; Myriad higher
|
3/10/2006 | BT | Market Commentary: Insmed, Corautus off on deals; NPS Pharma gains, dives on FDA; CV Therapeutics higher; Kos up
|
3/10/2006 | BT | NPS Pharmaceuticals receives FDA approvable letter for Preos
|
3/9/2006 | BT | Market Commentary: NPS Pharma weak ahead of FDA; Dyax plunges; Insmed up slightly; Vertex dives; Elan off, Biogen up
|
2/28/2006 | BT | Jefferies puts NPS at buy
|
2/28/2006 | BT | JMP keeps NPS at market outperform
|
2/27/2006 | BT | NPS to advance clinical development of teduglutide as treatment for Crohn's disease
|
2/24/2006 | BT | Merrill keeps NPS at buy
|
2/24/2006 | BT | JMP keeps NPS at market outperform
|
2/23/2006 | BT | NPS, Nycomed get committee OK to market Preotact/Preos parathyroid hormone in Europe
|
2/17/2006 | BT | NPS at market outperform by JMP
|
2/17/2006 | BT | Market Commentary: Cytyc shares, convertibles gain big; Alkermes slips on FDA news; NPS Pharma off amid uncertainty
|
2/17/2006 | BT | Merrill maintains NPS at buy
|
2/17/2006 | BT | Jefferies puts NPS at buy
|
2/13/2006 | BT | JMP reiterates NPS at market outperform
|
2/8/2006 | BT | NPS, AstraZeneca research and development collaboration extended
|
1/25/2006 | BTCV | NPS Pharmaceuticals files debt, stock shelf
|
1/18/2006 | BT | JMP says select small-, mid-cap biotech stocks look promising
|
1/13/2006 | BT | JMP reiterates NPS at market outperform
|
1/12/2006 | BT | Market Commentary: OSI punishment over Eyetech buy continues; NPS up; PDL plunges; Genta; Favrille, Illumina all higher
|
1/9/2006 | BT | Market Commentary: Human Genome, Amgen higher on license pact; Alnylam soars on 2006 view; NPS, Oscient up big
|
11/7/2005 | BT | JMP reiterates NPS at market outperform
|
11/7/2005 | BT | Merrill Lynch maintains NPS at buy
|
11/7/2005 | BT | Jefferies reiterates NPS at buy, $16 target
|
11/4/2005 | BT | Market Commentary: Introgen's stock lifts on Colgate-Palmolive alliance; Cytori, Olympus enter into joint venture
|
11/4/2005 | CV | Market Commentary: Qwest, Chesapeake remain active; Celgene up, Emdeon lower; King sideways
|
11/3/2005 | BT | JMP reiterates NPS at outperform
|
10/24/2005 | BT | NPS teams with Allergan to promote Restasis to rheumatologists
|
10/24/2005 | BT | Merrill Lynch maintains NPS at buy
|
9/28/2005 | BT | NPS Pharma reiterated by JMP at market outperform
|
9/28/2005 | BT | NPS Pharma reiterated by Jefferies at buy
|
9/8/2005 | BT | New Issue: NPS Pharma raises $79.45 million in follow-on at $11.35, discounted from $12.15 close
|
9/8/2005 | BT | Market Commentary: Myogen, NPS float follow-ons; Nektar halted during FDA panel; Sepracor up in face of generic filing
|
9/7/2005 | BT | NPS Pharma reiterated by Jefferies at buy
|
8/22/2005 | BTCV | NPS Pharmaceuticals files $200 million shelf
|
8/19/2005 | BT | NPS Pharmaceuticals reiterated at buy by Jefferies
|
7/27/2005 | BT | NPS Pharma price target cut by Merrill
|
7/27/2005 | BT | NPS Pharma kept by JMP at market outperform
|
7/27/2005 | BT | NPS Pharma maintained by Jefferies at buy
|
7/27/2005 | BT | Market Commentary: Theravance rises; NPS Pharma off; Advanced Life Sciences IPO on for Thursday; Elan, Biogen slightly higher
|
7/11/2005 | BT | NPS Pharma maintained by Merrill at buy
|
6/24/2005 | BT | Market Commentary: HemoSense IPO delayed yet again; Cephalon off, Alkermes up on pact for alcoholism shot; Genentech up
|
6/24/2005 | CV | Market Commentary: Convertibles mostly extend losses a second day; biotechs waver, but some energy issues see more gains
|
10/12/2004 | CV | Market Commentary: Apex Silver hovers around par; Amkor firms as bids hit; NPS Pharma, biotechs suffer
|
9/9/2003 | CV | Market Commentary: Cummins gains as buyers step in; Alpharma deeply wounded by lower guidance; telecoms slide
|
7/9/2003 | CV | NPS Pharmaceuticals says greenshoe exercised, raising convertibles to $192 million
|
6/12/2003 | CV | Market Commentary: Yield-grabbers reach for busted convertibles, distressed issues; new paper mixed in secondary
|
6/11/2003 | CV | New Issue: NPS Pharmaceuticals upsized $170 million convertibles yield 3%, up 35%
|
6/11/2003 | CV | Market Commentary: Xerox emerges as a mandatory; Mirant in freefall; Tyco gains on unit sale talk; airlines fly high
|